Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK1 Inhibition in Sarcoidosis
NCT05696795Phase 2Completed
- Sponsor
- Yale University
- Start
- Jun 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abrocitinib in sarcoidosis, sponsored by Yale University. Started Jun 2023; status: completed.
02
Drugs
abrocitinib
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on NCT05696795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05696795.